Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

SRZN vs LYRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–1 Matrix Metrics)

SRZN Overall Winner 6-Pillar Tally: SRZN 4 – 1 LYRA (1 Tie) Matrix Metrics: SRZN 6 – 1 LYRA

As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SRZN carries a Unified Composite Score of 33.2/100 (SELL) at $29.93 (N/M Forward P/E, -485.4% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin).

  • Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (6–1 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -25032.0% operating margin) and revenue trajectory (+408.6% vs. -87.2% YoY).
  • Technical & Structure Timing Caution: SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs LYRA
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.93
-7.38% 1D
Market Cap $602.5M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.28β · 66% Vol
Unified Composite Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.9% over 20 days), RSI 53
RSI-14: 53.1 · SMA20: $29.76 · SMA50: $26.28
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82

6-Pillar Scorecard Institutional Category Breakdown (SRZN 4 – 1 LYRA)

Columns: Metric · SRZN · LYRA
1. Valuation Multiples LYRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 48.3x 3.9x
2. Growth & Scale SRZN
Revenue Growth (YoY) +408.6% -87.2%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $11M $600,000
Market Cap $602.5M $2.3M
3. Profitability & Quality SRZN
Gross Margin N/A N/A
Operating Margin -485.4% -25032.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.8% -404.5%
4. Balance Sheet & Cash Flow SRZN
Cash Generation (TTM) -$31M -$32M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $95M Net Cash -404.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.0% (5th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (6) vs LYRA (1)
Institutional Metric SRZN LYRA Criterion Row Edge
Market Capitalization
Scale
$602.5M $2.3M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+408.6% -87.2% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-485.4% -25032.0% Higher Margin SRZN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.8% -404.5% Higher ROE SRZN
52-Week Range Position
Momentum
69% ($12–$38) 1% ($0–$38) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.28β · 66% Vol 0.33β · 248% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
33.2 / 100 (SELL) 52.2 / 100 (HOLD) Higher Composite LYRA
Trailing 12M Revenue (USD)
Operating Scale
$11M $600,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 48.3x EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) -$32M EBITDA (-404.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +65.14 pp
SRZN: +2.64% · LYRA: -62.5%
3M Horizon SRZN +94.72 pp
SRZN: +7.1% · LYRA: -87.62%
6M Horizon SRZN +183.6 pp
SRZN: +96.46% · LYRA: -87.14%
1Y Horizon SRZN +183.6 pp
SRZN: +96.46% · LYRA: -87.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRZN Revenue LYRA Revenue SRZN Op. Margin LYRA Op. Margin Margin Leader
FY2021 N/A $0M N/A -15303.5% LYRA
FY2022 $10M $0M -354.7% -4131.0% SRZN
FY2023 N/A $0M N/A -4308.1% LYRA
FY2024 $10M $0M -239.7% -6280.8% SRZN
FY2025 $0M $0M -1210.6% -7794.5% SRZN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
38d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs LYRA Key Questions & Quantitative Answers

As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SRZN carries a Unified Composite Score of 33.2/100 (SELL) at $29.93 (N/M Forward P/E, -485.4% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (6–1 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -25032.0% operating margin) and revenue trajectory (+408.6% vs. -87.2% YoY). Technical & Structure Timing Caution: SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with LYRA at -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin). Across the 5-period historical trajectory (FY2021 to FY2025), SRZN cumulative revenue shifted +0.0% while LYRA shifted N/A. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LYRA.

LYRA screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin), whereas LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus LYRA (-404.5% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 66% Vol realized risk). By comparison, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.